The Age-Related Eye Disease Study (AREDS) recommended treatment with antioxidants plus zinc in patients with intermediate or advanced age-related macular degeneration in order to reduce progression risks. Recent pharmacogenetic studies have reported differences in treatment outcomes with respect to variants in genes for CFH and ARMS2, although the treatment recommendations based on these differences are controversial. Different retrospective analyses of subsets of patients from the same AREDS trial have drawn different conclusions. The practicing clinician, who is not an expert on genetics, clinical trial design, or statistical analysis, may be uncertain how to interpret these results. Based on the balance of the available literature, we suggest not changing established practice recommendations until additional evidence from clinical trials becomes available.
Pharmacogenetics and nutritional supplementation in age-related macular degeneration
Blake M Hampton,Jaclyn L Kovach,S. G. Schwartz
Published 2015 in Clinical Ophthalmology
ABSTRACT
PUBLICATION RECORD
- Publication year
2015
- Venue
Clinical Ophthalmology
- Publication date
2015-05-15
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-20 of 20 references · Page 1 of 1
CITED BY
Showing 1-11 of 11 citing papers · Page 1 of 1